Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BRG0001
- Development stage
- Preclinical
- Lead developer
- BPGBio
01
Overview
BRG0001 is a preclinical drug candidate being developed by BPGbio (formerly Berg Health) for the treatment of conditions involving pathological angiogenesis. It was identified using BPGbio's Interrogative Biology® platform, which utilizes AI and multi-omics data to map disease biology. While specific molecular targets and modalities have not been publicly disclosed, the program is categorized under the company's drug discovery pipeline as an anti-angiogenic agent, likely intended for oncology or other vascular-related indications.
Beyond the preview
Go deeper on BRG0001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BRG0001.